Acute ischaemic stroke

Definition Stroke is characterised by rapidly developing clinical symptoms and signs of focal, and at times global, loss of cerebral function lasting more than 24 hours or leading to death, with no apparent cause other than that of vascular origin.1 Ischaemic stroke is defined as stroke due to vascular insufficiency (such as cerebrovascular thromboembolism) rather than haemorrhage. #### Interventions Acute ischaemic stroke ##### Beneficial: Stroke units Aspirin ##### Trade-off between benefits and harms: Thrombolytic treatment ##### Likely to be ineffective or harmful: Immediate systemic anticoagulation Acute reduction of blood pressure Intracerebral haematomas ##### Unknown effectiveness: Evacuation Incidence/prevalence Stroke is the third most common cause of death in most developed countries.2 It is a worldwide problem: about 4.5 million people die from stroke each year. Stroke can occur at any age, but half of all strokes occur in people over 70 years old.3 Aetiology About 80% of all acute strokes are caused by cerebral infarction, usually resulting from thrombotic or embolic occlusion of a cerebral artery4; the remainder are caused either by intracerebral or subarachnoid haemorrhage. Prognosis About 10% of all people with acute ischaemic strokes will die within 30 days of stroke onset.5 Of those who survive the acute event, about 50% will experience some level of disability after six months.6 Aims To achieve rapid restoration and maintenance of blood supply to the ischaemic area in the brain, and to minimise brain damage and hence impairment, disability, and secondary complications. Outcomes Risk of death or dependency (generally assessed as the proportion of people dead or requiring physical assistance for transfers, mobility, dressing, feeding, or toileting three to six months after stroke onset7); quality of life. Clinical Evidence researchers searched the Cochrane Library and the Cochrane Stroke Review Group database in 1998 and performed an update search and appraisal for systematic reviews and subsequent randomised controlled trials (RCTs) in June 1999. Question: What …

[1]  J Bamford,et al.  The frequency, causes and timing of death within 30 days of a first stroke: the Oxfordshire Community Stroke Project. , 1990, Journal of neurology, neurosurgery, and psychiatry.

[2]  P. Bath,et al.  Interventions for deliberately altering blood pressure in acute stroke. , 2001, The Cochrane database of systematic reviews.

[3]  B. Norrving,et al.  Stroke units in their natural habitat: can results of randomized trials be reproduced in routine clinical practice? Riks-Stroke Collaboration. , 1999, Stroke.

[4]  J. Slattery,et al.  Blood pressure and risk of stroke in patients with cerebrovascular disease , 1996, BMJ.

[5]  D. Warner.  Meta-analysis of oral nimodipine trials in acute ischemic stroke , 1995 .

[6]  Joseph P. Broderick,et al.  Effects of tissue plasminogen activator for acute ischemic stroke at one year , 1999 .

[7]  D. Barer,et al.  Low dose β blockade in acute stroke (“BEST” trial): an evaluation , 1988 .

[8]  J Bamford,et al.  A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project 1981-86. 1. Methodology, demography and incident cases of first-ever stroke. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[9]  N. Wahlgren,et al.  Intravenous Nimodipine West European Stroke Trial (INWEST) of Nimodipine in the Treatment of Acute Ischaemic Stroke , 1994 .

[10]  P. Sandercock,et al.  A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project--1981-86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage. , 1990, Journal of neurology, neurosurgery, and psychiatry.

[11]  P. Sandercock,et al.  Anticoagulants for acute ischaemic stroke. , 2015, The Cochrane database of systematic reviews.

[12]  R L Hewer,et al.  Functional abilities after stroke: measurement, natural history and prognosis , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[13]  J. Slattery,et al.  Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin--analysis of gastrointestinal bleeding during the UK-TIA trial. , 1995, Gut.

[14]  S. Ebrahim,et al.  Low dose beta blockade in acute stroke ("BEST" trial): an evaluation. , 1988, British medical journal.

[15]  S. Hatano,et al.  Experience from a multicentre stroke register: a preliminary report. , 1976, Bulletin of the World Health Organization.

[16]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[17]  J. G. Evans,et al.  The epidemiology of stroke. , 1979, Age and ageing.

[18]  P. Sandercock,et al.  Antiplatelet therapy for acute ischaemic stroke. , 2008, The Cochrane database of systematic reviews.

[19]  K. Prasad,et al.  Surgery for primary supratentorial intracerebral haemorrhage. , 2000, The Cochrane database of systematic reviews.

[20]  P. Bath,et al.  What Is the Correct Management of Blood Pressure in Acute Stroke? The Blood Pressure in Acute Stroke Collaboration , 1997 .

[21]  G. Hankey,et al.  Surgery for primary intracerebral hemorrhage: is it safe and effective? A systematic review of case series and randomized trials. , 1997, Stroke.

[22]  J. Schrader,et al.  Hypertension and stroke – rationale behind the ACCESS trial , 1998, Basic Research in Cardiology.